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1. Introduction
Rheumatoid  arthritis  (RA)  is  characterized  by  the  destruction  of  peripheral  joints  in
which  articular  cartilage  and  subchondral  bone  are  destroyed  by  chronic  proliferative
synovitis.  This  damage  often  leads  to  significant  loss  of  joint  function  and  impairs  the
ADL of patients with RA.
Most patients with RA are in use of traditional disease modifying antirheumatic drugs
(DMARDs) to control disease activity, and among the traditional, non-biological DMARDs
(nbDMARDs), methotrexate (MTX) is a first line and an anchor drug for the treatment of
RA. Currently introduced biologic agents, especially anti-tumor necrosis factor-alpha (TNF-
α) agents, have revolutionized the treatment of RA. TNF-α triggers the inflammatory cas‐
cade and stimulates the production of matrix degradable proteinases such as matrix
metalloproteinases, which well known to play a major role in the proteolytic degradation of
extracellular matrix macromolecules of cartilage and bone, which is a key step in joint de‐
struction in RA. Anti-TNF-α agents are now in routine use for RA patients who have failed
to respond to nbDMARDs, and have been demonstrated to improve the clinical symptoms
and delay joint destruction dramatically. Unfortunately, despite of the administration of
nbDMARDs and/or biologic agents, complete prevention of the destruction of the affected
joints is still not achieved. Over the course of their lifetime, many patients with RA may re‐
© 2013 Komiya and Terada; licensee InTech. This is an open access article distributed under the terms of the
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quire orthopaedic surgical interventions, such as total joint arthroplasty (TJA), arthrodeis,
reconstructive surgeries, cervical stabilization, and so on.
For orthopaedic surgeons, post-operative surgical site infections (SSI) and delayed wound
healing are major concerns, especially in TJA. Prosthetic infection is associated with pro‐
longed antibacterial therapy and hospitalization, functional decline, depression, shorter
prosthesis durability, which have great impact on morbidity, mortality and quality of life.
The baseline infection risk is increased 13-fold in individuals with RA when compared with
the general population [1]. In addition, receiving anti-TNF-α agents showed an increased
risk of serious infections. Delayed wound healing or wound dehiscence is also believed to
occur more frequently in patients with RA. Patients with RA are already predisposed to im‐
paired wound healing as a result of reduction in skin thickness above that which is due to
steroid use. Furthermore TNF-α is required for normal wound healing, and in experimental
settings anti-TNF-α has been linked to poor wound healing [2]. Thus careful management of
anti-rheumatic agents and their adverse effects in a perioperative period is essential. Among
nbDMARDs, only MTX has been investigated prospectively and randomized manner, and
demonstrated that continuation of MTX treatment did not increase the risk of either infec‐
tions or surgical complications in elective orthopaedic surgery in patients with RA [3]. As
for biologic anti-TNF-α agents, current national guidelines suggested that treatment with bi‐
ologic agents should be discontinued during the perioperative period. Although discontinu‐
ation of anti-TNF-α agents during the perioperative period may have a positive effect on SSI
and wound healing rates, but this is at the expense of increased risk of RA flare that could
affect postoperative rehabilitation. However, there are no prospective clinical trials and few
studies assessing the use of anti-TNF-α agents during the perioperative periods in RA pa‐
tients undergoing elective orthopaedic surgery. In this chapter, we review the available liter‐
ature related to perioperative complications, especially SSI, delayed wound healing and RA
flare in elective orthopaedic surgery in patients with RA treated with anti-TNF-α agents,
and discuss the perioperative management of anti-TNF-α agents, the clinical dilemma
whether discontinue or not.
2. Risk of septic arthritis (SA) in RA patients
Individuals with RA are at an inherently increased risk of infection [1, 4]. Edwards et al. [1]
reported that the incidence rate for SA was 12.9 times higher in subjects with RA than those
without [95% confidence interval (CI) 10.1-16.5]. Doran et al. [4] performed a retrospective
longitudinal cohort study and reported that the overall rate of infection per 100 person-years
was higher in RA patients (19.64) than in non-RA patients (12.87), and the rate ratio for de‐
veloping infections in patients with RA was 1.53 (95% CI 1.41-1.65). Infection sites that were
associated with the highest rate ratio were the joints (rate ratio for SA 14.89 [95% CI
6.12-73.71]), bone (rate ratio for osteomyelitis 10.63 [95% CI 3.39-126.81]), and skin and soft
tissues (rate ratio 3.28 [95% CI 2.67-4.07]) [4]. SA is a serious and severe condition for pa‐
tients that can lead to irreversible joint destruction, and the incidence of SA in the general
population is around 4-10/100,000/person-years [5, 6]. SA is lethal around 10% of a death
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rate [7]. In fact, infections requiring hospitalization were significantly more frequent in RA
patients (9.57/100 person-years) than in non-RA patients (5.09/100 person-years) with rate
ratio 1.88 (95% CI 1.71-2.07), and SA was also associated with a highest rate ratio of 21.66
(95% CI 7.37-257.61)] [4].
Accumulated data indicate that the risk factors for SA are increasing age, comorbidities (dia‐
betes mellitus, chronic renal failure, chronic cardiac failure), joint prosthesis, skin infection
and pre-existing joint damage [1, 8-10], but whether RA treatment with nbDMARDs, corti‐
costeroids and biologics including anti-TNF-α agents increases the risk of SA is still unclear.
DMARDs and biologics including anti-TNF-α agents are generally believed to be immuno‐
suppressive and likely to increase the incidence of SA in patients with RA. But the data on
these are very limited and sparse. Edwards et al. [1] performed a retrospective study using
the United Kingdom General Practice Research Database to analyze the effect of DMARDs
on developing SA in patients with RA. There was significantly increased risk of SA in indi‐
viduals with RA prescribed DMARDs compared with those not prescribed DMARDs. The
incidence rate ratios (IRR) for developing SA in the patients receiving DMARDs compared
with receiving no DMARDs were different for different medications. Penicillamine (adjust‐
ed IRR 2.51, 95% CI 1.29-4.89, P=0.004), sulfasalazine (adjusted IRR 1.74, 95% CI 1.04-2.91,
P=0.03) and prednisolone (adjusted IRR 2.94, 95% CI 1.93-4.46, P<0.001) were associated with
an increased incidence of SA when compared with receiving no DMARDs [1]. The use of
other DMARDs (including MTX) not showed such effect [1]. There was a number of individ‐
uals with RA developed SA without receiving DMARDs, thus they considered that the im‐
mune dysfunction associated with RA and the coexistent joint damage are more important
risk factors than immunomodulatory therapies with DMARDs [1].
There is very limited information regarding the effect of anti-TNF-α therapy on the risk of
SA. Galloway et al. [11] conducted a prospective observational study to evaluate the risk of
SA in patients with RA treated with anti-TNF-α agents. They reported that incidence rates
for SA were anti-TNF 4.2/1000/patient years (95% CI 3.6-4.8) and nbDMARDs 1.8/1000/ pa‐
tient years (95% CI 1.1-2.7). The adjusted hazard ratio (HR) for SA in the anti-TNF cohort
was 2.3 (95% CI 1.2-4.4). The risk did not differ significantly between the three agents: inflix‐
imab (IFX), etanercept (ETN) and adalimumab (ADA). The hazard for SA in the anti-TNF
cohort was greatest in the early months of therapy, as well as data from other cohorts [12],
and the risk then decreased steadily over the remainder of the follow-up period [11]. One of
the potential explanations for early increased risk is that it may reflect a true reduction in
risk of joint infection in patients who achieve better control of their RA [11].
In summary of this section, patients with RA are at an increased risk of SA irrespective of
therapy. Some DMARDs and corticosteroid increase the risk of SA. Exposure to anti-TNF
therapy is also associated with an increased risk of SA and this risk was greatest in the first
year of treatment. Thus, this increased risk of SA in RA may be due to not only as a conse‐
quence of the disease nature of RA but also treatment with some immunomodulatory
agents. Current evidence does not support any one anti-TNF agent having a safer profile
with regard to SA.
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3. Risk of SSI in RA patients undergoing TJA
TJA is a major orthopaedic procedure for destructed joints. In RA, total knee arthroplasty (TKA)
and total hip arthroplasty (THA) are the most common, promised surgical interventions for pa‐
tients to recover from painful joints and impaired activities of daily life. However, prosthetic
joint infection often requires revision of the infected prosthesis and prolonged intravenous anti‐
microbial therapy, and has a mortality rate of 2.7-18% [13]. Patients with RA have been identi‐
fied to have a higher baseline risk of infectious diseases compared with general population. In
addition, the immunosuppressive drugs used in the treatment of RA may further increase the
risk of infection. Whether this increased baseline risk of infections in RA patients might influ‐
ence the risk of deep infection after primary TJA is somewhat conflicting.
Wymenga et al. [14] conducted a multicenter prospective study to investigate the association
between perioperative factors and SA after TKA and THA. At 1-year follow up, 9/362 pa‐
tients (2.5%) after TKA and 17/2651 patients (0.64%) after THA were completed by SA. They
reported that RA was a risk factor for SA for TKA (risk ratio 4.8; 95% CI 1.2-19), but they
could not confirm this in THA. Schrama et al. [15] reported a retrospective study using the
Norwegian Arthroplasty Register to examine the risk of revision arthroplasty due to infec‐
tion in RA (6,629 procedures) compared with OA patients (102,157 procedures). The inci‐
dence of revision due to infection in TKA and THA were 0.7% (176/24,294 procedures) and
0.6% (534/84,492 procedures), respectively. The risk of revision for infection in RA patients
with TKA was 1.6 (95% CI 1.06-2.38) times higher compared to OA patients, but there were
no difference in THA. This discrepancy between TKA and THA were also reported by Wy‐
menga et al. [14], and Schrama et al. mentioned that the vulnerable soft tissue envelope
around the knee joint could make the TKA in RA patients more susceptible to infection,
since the connective tissue disease RA and its potentially immunomodulating medication
are risk factors for skin and soft tissue infections. Jamsen et al. [16] analyzed primary (40,135
procedures) and revision (3,014 procedures) knee arthroplasties in a large series of knee ar‐
throplasties from Finnish Arthroplasty Register. In total, 387 reoperations were performed
for the treatment of infection (0.90%; 95% CI 0.81-0.99). The adjusted HR for reoperation due
to infection in primary and revision TKA in patients with RA were 1.86 (95% CI 1.31-2.63)
and 1.01 (95% CI 0.44-2.34) compared with primary OA, respectively. Robertsson et al. [17]
also reported using another large series of knee arthroplasties, the Swedish Knee Arthro‐
plasty Register that the risk of revision for infection was significantly higher in RA patients
compared to OA patients [risk ratio (RR) 1.4; 95% CI 1.1-1.9]. The data on influences of
nbDMARDs on the risk of prosthetic infection in patients with RA were absent in these
studies [14-17].
Bongartz et al. [13] conducted a retrospective study using the Mayo Clinic Total Joint Regis‐
try to examine the incidence and risk factors of prosthetic joint infection in RA patients (657
procedures; THA or TKA). 23 (3.7%) joint arthroplasties were complicated by infection. The
risk of prosthetic joint infections were increased in RA patients (HR 4.08, 95% CI 1.35-12.33)
compared with a matched cohort of OA patients. Revision arthroplasty (HR 2.99, 95% CI
1.02-8.75), previous prosthetic joint infection of the replaced joint (HR 5.49, 95% CI
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1.87-16.14), and operation time (HR 1.36 per 60-minitue increase, 95% CI 1.02-1.81) were sig‐
nificant predictors of postoperative prosthetic joint infection. Based on the pharmacokinetic
half-life and/or data on the biologic activity of each DMARD, perioperative DMARDs use
was judged as either withheld or maintained. DMARDs were withheld perioperatively in
57% of procedures and stopping DMARDs therapy at the time of surgery lowered the risk of
prosthesis infection (HR 0.65, 95% CI 0.09-4.95), but this was statistically not significant.
There were 3 prosthesis infections in 38 patients who were treated with anti-TNF agents at
the time of surgery as compared with no infection in 12 patients who stopped their anti-TNF
therapy prior to surgery, but this difference was not statistically significant. Perioperative
corticosteroid use was not associated with an increased risk of prosthesis infection.
Besides DMARDs, the risk of perioperative use of corticosteroids for prosthetic infection in
patients with RA is controversial. Berbari et al. [18] conducted a case-control study to deter‐
mine risk factors for the development of prosthetic joint infection. 462 episodes of prosthetic
joint infection in 460 patients were used for analysis. Univariate analysis identified that RA,
steroid therapy as risk factors for joint prosthetic infection with odds ratio (OR) of 2.0 (95%
CI 1.3-3.0) and 2.0 (95% CI 1.3-3.1) respectively. Wilson et al. [19] reported that 67 (1.6%) out
of the 4,171 TKA were complicated by infection. The incidence of infection in RA patients
(2.2%; 45/2076) was significantly higher than in OA (1%; 16/1857) (P<0.0001). Despite the fact
that a higher percentage of patients who had RA and infection had used steroids than had
those who did not have an infection (75% compared with 46%), a history of oral use of ste‐
roids was not a significant risk factor.
While most of papers agreed with increased risk of prosthetic infection in RA patients, da
Cunha et al. [20] conducted a retrospective study to compare the incidence of infections be‐
tween RA and OA patients in THA and TKA, and reported that no significant difference
was observed between the RA and OA groups regarding the rates of prosthesis infections
(TKA 7.1% vs. 0% and THA 2.1% vs. 0%, respectively, both with P>0.1), incisional infections
(TKA 14.3% vs. 3.3% and THA 4.3% vs. 1.3%, respectively, both with P>0.1), and systematic
infections (TKA 7.1% vs. 3.6%, P=0.92 and THA 4.3% vs. 10.7%, P>0.1, respectively). They
concluded that RA was not identified as a risk factor for perioperative infections in THA
and TKA in their case series. The low incidence of infections in both groups may explain
their findings. Although the data on usage and mean dose of DMARDs, biologics and corti‐
costeroids were reported, the association between prosthesis infection and these drugs were
not analyzed in this study.
Whether the use of nbDMARDs constitutes an independent risk factor for SSI remains un‐
clear. Among nbDMARDs, only MTX had been investigated in a prospective and random‐
ized study. Grennan et al. [3] reported that signs of infection or surgical complications
occurred in two of 88 procedures (2%) in the group of MTX continuation, 11 of 72 proce‐
dures (15%) in the group of MTX discontinuation, and 24 of 228 procedures (10.5%) in the
MTX naïve group. Furthermore, accumulated data support the perioperative use of MTX,
and international 3E Initiative stated in the recommendation that MTX can be safely contin‐
ued in the perioperative period in RA patients undergoing elective orthopaedic surgery [21].
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In summary of this section, most of studies support the increased prevalence of TJA infec‐
tion in RA patients. Among nbDMARDs, only MTX had been intensively investigated the
influences of the perioperative use on the risk of SSI, and accumulated data support the safe‐
ty of perioperative continuation of MTX undergoing elective orthopaedic surgery. We
should be aware that TJA in RA patients is high-risk in infection and sufficient antibiotic
prophylaxis should be taken with a careful follow-up.
4. Risk of SSI in RA patients treated with anti-TNF-α agents undergoing
orthopaedic surgery
The information about the risk of SSI in RA patients treated with anti-TNF-α agents undergoing
orthopedic surgery is very limited, and to date, there are only 14 studies on this matter.
We at first take up 4 studies those analyzed whether continuation of TNF blockers in perio‐
perative period increases the risk of SSI in patients on anti-TNF therapy.
Talwalker et al. [22] performed a small retrospective study. 16 procedures in 11 patients (RA;
n=10, psoriatic arthritis; n=1) on anti-TNF undergoing elective joint surgery were reviewed.
TNF blockers were continued in group A (4 procedures), while in group B (12 procedures), they
were withheld before surgery and restarted after the procedure. In group A, IFX was used in
one operation, the patient receiving the injection 3 days before surgery while ETN was used in
three patients. In group B, IFX was stopped nearly 4 weeks before surgery, whereas ADA and
ETN was stopped at 2 weeks. The timings for restarting the drug were variable. Postoperative‐
ly, none of the patients in either group developed serious wound and systematic infections, but
one flare up occurred in a patient receiving ETN in group B.
Wendling et al. [23] conducted a retrospective study with a sample size of 50 surgical proce‐
dures (foot and ankle; 13, hand and wrist; 11, TJA; 12, others; 14) in 30 patients with RA
treated with TNF blockers. TNF blockers at the time of surgery was IFX (n=26), ETN (n=13),
ADA (n=11), with a mean exposure of 12.1 months (range 1-42). TNF blockers were with‐
held before surgery in 18/50 patients, and for the rest, surgery was performed between two
TNF blocker injections. Postoperatively, no infections occurred in either group whether TNF
blocker was discontinued or not, but RA flares were observed in 6 cases (12%) and signifi‐
cantly associated with anti-TNF interruption before surgery (5 interruptions/6 cases of flare
vs. 13 interruption/44 surgical procedures without flare; Fisher’s exact value=0.02).
Den Broeder et al. [24] performed a large retrospective study. Two parallel cohorts were de‐
fined: cohort 1 did not use anti-TNF, cohort 2 used anti-TNF but had either stopped (2A) or
continued anti-TNF preoperatively (2B), the cutoff point being set at 4 times the half-life
time of the drug. In total, 1,219 procedures were performed (wrist/hand; 317, ankle/foot; 280,
knee; 195, hip; 172, shoulder; 114, elbow; 102, other; 39). Crude infection risk in cohorts 1,
2A, and 2B were 4.0% (41/1023), 5.8% (6/104), and 8.7% (8/92), respectively. History of prior
SSI or skin infection was found to be the strongest predictor for SSI (OR 13.8, 95% CI
5.2-36.7, P<0.0001), but perioperative use of anti-TNF was not significantly associated with
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an increase in SSI rates (OR 1.5, 95% CI 0.43-5.2, P=0.43). However, wound dehiscence occur‐
red more frequently in patients that continued anti-TNF compared to patients that tempora‐
rily discontinued anti-TNF treatment (OR 11.2, 95% CI 1.4-90).
Bongartz et al. [13] conducted a retrospective, single-center, double cohort study that includ‐
ed all patients with RA who underwent THA or TKA at the Mayo Clinic Rochester between
January 1996 and June 2004. 657 surgeries in 462 patients with RA were identified. There
were 3 prosthesis infections in 38 patients who were treated with anti-TNF agents at the
time of surgery as compared with no infection in 12 patients who stopped their anti-TNF
therapy prior to surgery. However, the result did not reach statistical significance.
Secondary, we take up 7 studies which compare the perioperative risk of infection between
patients on TNF blockers and those on nbDMARDs.
Bibbo et al. [25] reported a 12-month prospective study that compared foot and ankle sur‐
gery in 16 RA patients (mean age 50 years) on TNF blockers (group 1) (IFX; 5, ETN; 11) com‐
pared with 15 controls (mean age 60 years) on nbDMARDs (group 2). Patients on TNF
blockers discontinued treatment prior to surgery (ETN; mean 2.6 days, IFX; mean 20.2 days)
and resumed treatment postoperatively. Infectious complications occurred in two patients:
one case of a superficial infection in a group 1 patient and one case of a deep infection (os‐
teomyelitis) in a group 2 patient. Delayed wound healing occurred in three patients, all oc‐
curred in group 2. Bone healing complications occurred in three patients, all in group 2,
comprised of two nonunions and one delayed union. When considered individually, the oc‐
currence of an infectious or healing complication proved to be statistically similar between
groups 1 and 2. However, when complications summed (infectious and healing complica‐
tions), group 2 demonstrated a statistically higher overall complication rate (P=0.033, Fish‐
er’s exact test). They concluded that the use of TNF blockers may be safely undertaken in the
perioperative period without increasing the risk of infectious or healing complications in the
patients with RA undergoing elective foot and ankle surgery.
Hirano et al. [26] performed retrospective cohort study where adverse events of surgical
wounds were compared between patients treated with TNF blockers (n=39) (IFX; 24, ETN;
15) and those on nbDMARDs (n=74). TKA is the commonest surgery followed by THA. Ad‐
ministration of TNF blockers was stopped prior to surgeries (IFX; mean 29.8 days, ETN;
mean 9.6 days) and restarted after surgical wounds were completely healed. Adverse events
of surgical wounds occurred after two operations in the TNF group (5.1%) and five opera‐
tions in the nbDMARDs group (6.8%), which was not statistically significant difference by
Fisher’s exact test (P=1.0000). OR was 0.7459 (95% CI 0.1380-4.0336). Although most of ad‐
verse events of surgical wounds were wound dehiscence and continuation of discharge,
postoperative infection occurred in one TKA in the TNF group. They concluded that the use
of anti-TNF agents dose dot cause specific adverse events on surgical wounds after elective
orthopedic surgeries in RA patients.
Kawakami et al. [27] performed a retrospective case-control study to identify perioperative
complications associated the use of TNF blockers. RA patients on anti-TNF (64
procedures/49 patients) were compared to those on nbDMARDs (64 procedures/63 patients).
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TKA is the commonest surgery followed by THA. TNF blockers (IFX; 35 and ETN; 29) were
withheld 2-4 weeks prior to surgery according to the British Society for Rheumatology and
the Japan College of Rheumatology guidelines (2-4 weeks for ETN, 4 weeks for IFX). Multi‐
variate logistic regression analysis identified the use of TNF blockers (OR 21.80, 95% CI
1.231-386.1, P=0.036), prednisone dosage (OR 1.433, 95% CI 1.007-2.040, P=0.046), and dis‐
ease duration (OR 1.169, 95% CI 1.030-1.326, P=0.015) as a risk factors for SSI. SSIs were de‐
veloped 12.5% (8/64) in the anti-TNF group, whereas 2% (1/64) in the nbDMARDs group
(P=0.016), but there was no delayed wound healing occurred in either groups. RA flare-ups
during the perioperative periods were found in 17.2% (11/64) of anti-TNF group. These
flare-ups were significantly increased in ETN group (31.0%, 9/29) compared with the IFX
group (5.7%, 2/35) (P=0.009). Multivariate logistic regression analysis also revealed that the
use of TNF blockers was the only risk factors for DVT (OR=2.83, 95% CI 1.10-7.25, P=0.03) in
their study. DVT were developed 51% (23/45) in the anti-TNF group, whereas 26% (12/45) in
the nbDMARDs group (P=0.015). They concluded that TNF blockers were likely cause SSI
and DVT in RA patients undergoing elective orthopaedic surgery.
Momohara et al. [28] performed a retrospective study to identify risk factors for acute SSI
after TJA (THA; 81, TKA; 339) in RA patients treated with biologics (48 patients, THA; 11,
TKA; 37) and nbDMARDs (372 patients). In the biologics group, 19 (4.5%) received IFX, 23
(5.5%) received ETN, two (0.5%) received ADA, and four (1.0%) received tocilizumab (TCZ).
Of the patients undergoing THA or TKA, 24 cases (5.7%) developed a superficial incisional
SSI requiring the use of antibiotics and the three cases (0.7%) developed an organ/space SSI
necessitating surgical treatment to remove the artificial joint prosthesis. Multivariate logistic
regression analysis revealed that the use of biologics (OR=5.69; 95% CI 2.07-15.61, P=0.0007)
and longer RA duration (OR=1.09; 95% CI 1.04-1.14, P=0.0003) were the only significant risk
factors for acute SSI. Furthermore, multivariate logistic regression analysis of individual
medication (nbDMARDs and biologics) adjusted for disease duration indicated that TNF
blockers increased the risk of SSI (IFX OR=9.80; 95% CI 2.41-39.82, P=0.001; ETN OR=9.16;
95% CI 2.77-30.25, P=0.0003). They found that the use of biologics (IFX or ETN) and longer
disease duration were associated with an increased risk of acute SSI in RA patients.
The Committee on Arthritis of the Japanese Orthopedic Association [29] investigated the
prevalence of postoperative complications in patients with RA in teaching hospitals in Ja‐
pan. The number of surgical procedures under treatment with biologic agent was 3,468 (IFX;
1,616, ETN; 1686, ADA; 41, TCZ; 102, abatacept; 23) and the prevalence of infection was 1.3%
(46 procedures). For IFX, ETN, and TCZ, the mean times of withdrawal before surgery were
26.4, 14.1, and 19.8 days, respectively. The prevalence of infection was 1.0% (567 procedures)
in 56,339 procedures under treatment with nbDMARDs. There were no significant differen‐
ces between biologics and nbDMARDs groups with respect to the prevalence of infections
(OR 1.32, 95% CI 0.98-1.79, P=0.07). In the joint arthroplasty group, the prevalence of infec‐
tion was 2.1% (34/1,626 procedures) in biologics group and 1.0% (298/29,903 procedures) in
nbDMARDs group. There was a significant difference between biologics and nbDMARDs
groups (OR 2.12, 95% CI 1.48-3.03, P<0.0001). They concluded that the infection risk of joint
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arthroplasty in RA patients on anti-TNF therapy was more than twofold greater compared
with those treated with nbDMARDS.
Kubota et al. [30] performed a retrospective study to analyze the influence of biological
agents on delayed wound healing and the postoperative SSI in RA patients. The patients
were divided into two groups, those treated with biologics (bio group; 276 joints) and not
treated with biologic agents (non-bio group; 278 joints). Biologics administered in the bio
group were IFX (n=14), ETN (n=236), ADA (n=8), and TCZ (n=18), and these agents were
withheld 2-4 weeks before surgery. TKA is the commonest surgery followed by THA. In the
bio group, postoperative superficial and deep infection developed in one and two joints, re‐
spectively. In the non-bio group, superficial infection developed in one joint, and deep infec‐
tion was not observed. The incidence of SSIs did not differ significantly between the two
groups (Mann-Whitney U-test, P=0.31251). Delayed wound healing occurred in 15 joints
(5.4%) in the bio group (all the patients were treated with ETN), and 12 joints (4.3%) in the
non-bio group, but the difference was not statistically significant (Mann-Whitney U-test,
P=0.522). They concluded that the use of biologics may not affect the incidence of postopera‐
tive adverse events related to SSI and wound healing.
Hayata et al. [31] performed a retrospective study to investigate the complications of ortho‐
peadic surgery for RA patients treated with IFX (52 patients). Commonest surgery was ar‐
throscopic synovectomy (n=30), followed by TJA (n=16). The mean timing of surgery after
infusion of IFX was 4 weeks. There were two cases (3.8%) of superficial wound infection
(one case was foot arthroplasty and the other was spine surgery), but there was no deep
wound infection. Furthermore, there is no correlation between infection and clinical factors
including age, disease duration, preoperative CRP, MMP-3, rheumatoid arthritis particle-ag‐
glutination (RAPA) and the period until surgery after IFX infusion. They concluded that IFX
did not increase the risk of either infection or surgical complications occurring in patients
with RA within 1 year of orthopeadic surgery.
Thirdly, we take up 3 studies which compare the patients with postoperative infection and
those without, to identify the association between anti-TNF therapy and the risk of infection.
Gilson et al. [32] carried out a retrospective case-control study using French RATIO registry
to analyze the risk factors for TJA infections in patients receiving TNF blockers. 20 patients
(18 with RA) treated with TNF blockers (IFX; 7, ETN; 5, ADA; 8) and presented with TJA
infections were compared to controls (40 patients) without TJA infections on TNF blockers.
TJA infections concerned principally the knee (n=12, 60%) and the hip (n=5, 25%). 8 cases
(40%) versus 5 controls (13%) had undergone primary or revision TJA for the joint subse‐
quently infected during the previous year (P=0.03). Of these procedures, TNF blockers were
continued in 5 cases compared to 1 in the control group (P=0.08). Multivariate analysis dem‐
onstrated that the predictors of infection were primary TJA or TJA revision for the joint sub‐
sequently infected within the last year (OR 88.3, 95% CI 1.1-7071.6, P=0.04) and increased
daily steroid intake (OR 5.0 per 5 mg/day increase, 95% CI 1.1-21.6, P=0.03). They concluded
that TJA infection was rare but potentially severe in patients receiving TNF blockers. Impor‐
tant risk factors were primary TJA or TJA revision for the joint subsequently infected within
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the last year, particularly when TNF blockers were not interrupted before surgery, and the
daily steroid intake.
Giles et al. [33] performed a retrospective study to investigate the association between anti-
TNF therapy and the development of serious postoperative infection in RA patients under‐
going orthopaedic surgery. 91 patients were identified as having at least one orthopedic
procedure, and 10 of the 91 patients (11%) developed serious postoperative infection. The
demographic features and RA therapies between infection group (n=10) and no infection
group (n=81) were comparable. But infection group (7/10 patients; 70%) were significantly
more likely treated with TNF-α blocker at the time of surgery compared with no infection
group (28/81 patients; 35%) (P=0.041). Univariate analysis revealed that anti-TNF was signif‐
icantly associated with the development of postoperative infections (OR 4.4, 95% CI
1.10-18.41). This association remained statistically significant after adjustment for age, sex,
and disease duration (OR 4.6, 95% CI 1.1-20.0); prednisone use, diabetes, and serum rheu‐
matoid factor status (OR 5.0, 95% CI 1.1-21.9); and all these 6 variables simultaneously (OR
5.3, 95% CI 1.1-24.9). They concluded that treatment with TNF blockers associated with in‐
creased risk of early infectious complications following orthopaedic surgery in patients with
RA. They suggest that TNF blockers should be withheld prior to orthopaedic surgery.
Ruyssen-Witrand et al. [34] performed a systematic retrospective study to assess the complica‐
tion rates after surgery in rheumatic patients treated with TNF blockers. 127 surgical proce‐
dures (107 orthopaedic procedures, 84.3%) performed in 92 rheumatic patients (71 RA patients,
77.2%) receiving TNF blockers. Orthopaedic procedures had a postoperative complication rate
of 12% (n=13) with 5.6% (n=6) of infections, whereas ‘clean’ orthopedic procedures such as joint
replacement or vertebral surgery had a complication rate of around 10% (n=4) with 7% (n=3) in‐
fections. Among the procedures where TNF blockers were discontinued more than 5 half-lives
before surgery (36 procedures), there were 19.4% (7/36) complications compared to 18.4%
(12/65) for procedures where anti-TNF therapy was interrupted less than 5 half-lives before or
was not interrupted at all (P=0.48). If therapy was discontinued for more than 2 half-lives the
complication rate was 17.6%, versus 30.0% if therapy was discontinued less than 2 half-lives be‐
fore or was not discontinued (P=0.24). Thus, interrupting TNF blockers did not decrease the
postoperative complications. No risk factors, either demographic or for severity, were statisti‐
cally significant in predicting post-surgical complications. Analysis of treatments showed more
complications with ADA (28.6%) than ETN (11.5%), but this was not statistically significant
(P=0.18). The cumulative corticosteroid dose was higher in the group with postoperative com‐
plications, but this was not also statistically significant. The authors concluded that the postop‐
erative complication rate is high in patients treated with TNF blockers, thus discontinuing TNF
therapy before surgery should be considered.
In summary of this section, it is difficult to make definite conclusion on the association be‐
tween anti-TNF therapy and SSI in RA patients undergoing orthopedic surgery due to the
retrospective nature and small sample size of most of reported studies. In 4 studies [13,
22-24], perioperative continuation of anti-TNF therapy did not increase the risk of SSI,
whereas in 3 studies [27-29], the risk of SSI was increased in anti-TNF therapy group, re‐
gardless of discontinuation of the therapy perioperatively. Another point of view, preopera‐
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tive discontinuation of TNF blockers causes the reduction of effects of the agents at the
operation date, thus the results of these studies may not show the accurate influences of
TNF blockers on the risk of SSI. However, in the other four studies [25, 26, 30, 31], appropri‐
ate preoperative discontinuation of TNF blockers did not increase the risk of SSI compared
with group on nbDMARDs. The risk factors for SSI, which most of RA patients undergoing
TJA are considered to have, reported in 17 studies were the use of TNF blockers (OR 21.80
[27], OR 5.69 [28], and OR 4.4 [33]), prednisone dosage (OR 1.433) [27], increased daily ste‐
roid intake (OR 5.0 per 5mg/day increase) [32], longer disease duration (OR 1.169 [27] and
OR 1.09 [28]), history of prior SSI or skin infection (OR 13.8) [24], primary or revision TJA for
the joint subsequently infected within the last year (OR 88.3) [32], and “clean” surgical pro‐
cedure such as TJA (OR 2.12) [29]. Thus, it may be preferable to perform TJA, if needed, be‐
fore the induction of TNF blockers [32]. In cases of prosthetic surgery after induction of TNF
blockers, their withdrawal during the perioperative period is highly recommended and ste‐
roid intake should be reduced as low as possible before surgery [32].
Further larger prospective studies are clearly needed to make clear the association between
perioperative use of TNF blockers and SSI, and in clinical practice until these studies are
done, we should discontinue TNF blockers and take a sufficient antibiotic prophylaxis with
a careful follow-up.
5. Risk of wound healing complications in RA patients treated with anti-
TNF-α agents
Patients with RA are already predisposed to impaired wound healing as a result of reduc‐
tion in skin thickness [2, 35]. Thus, many orthopaedic surgeons consider the risk of wound
healing complication to be high in RA patients, especially treated with TNF blockers [36].
Wound healing is a complex process and TNF-α is required for normal wound healing. An
“acute” wound healing process generally includes haemostasis/inflammation, proliferation
and tissue remodeling stages [37]. On the other hand, in a “chronic” wound, wound healing
is impaired and is characterized by excessive inflammation, enhanced proteolysis, and re‐
duced matrix deposition. Tarnuzzer et al. [38] demonstrated that the levels of TNF-α in fluid
from “chronic” wounds were approximately 100-fold higher than those in fluid from an
“acute” wound (mastectomy incision). However, the experimental data on the role of TNF-α
in wound healing is still controversial. Mooney et al. [2] reported that local application of
TNF-α increased wound disruption strength and eventually promoted wound healing,
whereas Rapala et al. [39] and Salomon et al. [40] reported that local application of TNF-α
down-regulated the synthesis of collagen and was detrimental to wound healing. Some
studies analyzed the effect of blockade of TNF-α on wound healing. Mori et al. [41] reported
that in TNF receptor p55-deficient mice, angiogenesis, collagen accumulation, and reepithe‐
lialization were up-regulated, and wound healing was accelerated eventually. Iglesias et al.
[42] analyzed wound healing in SWISS-OF1 mice and reported that surgical wounds
showed a higher degree of collagenization in ETN-treated versus untreated mice, with no
difference in the time course of wound healing. They concluded that anti-TNF therapy did
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not affect wound healing. Streit et al. [37] reported a case series of patients with “chronic”,
therapy-resistant leg ulcers responded well to topical application of IFX. Ashcroft et al. [43]
also reported that inhibiting TNF-α is a critical event in reversing the severely impaired
wound healing.
Surgical wound in elective orthopaedic surgery is basically considered as “acute” wound. In
the 9 of 17 studies taken up in section 4, the association between anti-TNF therapy and
“acute” wound healing complications in RA patients were reported as follows. Den Broeder
et al. [24] reported that wound dehiscence occurred more frequently in patients who contin‐
ued anti-TNF therapy (9/92 cases, 9.8%) compared to those temporarily discontinued anti-
TNF therapy (1/104 cases, 0.9%) (OR 11.2, 95% CI 1.4-90). Wendling et al. [23] reported that
three cases (6%) of delayed wound healing were recorded in patients on TNF blockers (50
surgical procedures). Ruyssen-Witrand et al. [34] reported that postoperative wound heal‐
ing complications occurred in 6 cases (4.7%) in patients treated with TNF blockers (127 sur‐
gical procedures). Kubota et al. [30] reported that delayed wound healing occurred in 15
joints (5.4%) in bio group and 12 joints (4.3%) in non-bio group, but the difference between
two groups was not statistically significant. Hirano et al. [26] reported that adverse events of
surgical wounds occurred after two operations (5.1%) in the TNF group (n=39) and five op‐
erations (6.8%) in the nbDMARDs group (n=74), but the difference between two groups was
not statistically significant. Suzuki et al. [29] reported that delayed wound healing occurred
in 14 cases (IFX; 2, ETN; 9, TCZ; 3) (0.4%) in biologics group (n=3,468). In the remaining 3 of
9 studies by Kawakami et al. [27], Momohara et al. [28], and Bibbo et al. [25], there was no
delayed wound healing in patients with anti-TNF therapy.
In summary of this section, the role of TNF-α in wound healing is still controversial. Anti-
TNF therapy seems to be preferable for improvement in healing of “chronic” wounds where
the level of TNF-α is excessive compared with “acute” wounds. Thus, perioperative discon‐
tinuation of anti-TNF therapy is preferable to decrease the risk of wound healing complica‐
tions, but reported data are controversial and insufficient to make clear conclusion about
this matter.
6. Perioperative discontinuation of anti-TNF-α agents and risk of RA
flare
For orthopaedic surgeons, one of the major concerns is whether perioperative discontinua‐
tion of TNF blockers results in flare up of the disease activity. Because RA flare may com‐
promise postoperative rehabilitation, which strongly affect the result of orthopaedic
surgery. However, the information about perioperative RA flare after discontinuation of an‐
ti-TNF therapy in perioperative period is very limited. Only some comments about the flare
were reported in 3 of 17 studies taken up section 4. Talwalker et al. [22] reported that one
flare up occurred postoperatively in a patient receiving ETN, but the flare up was well con‐
trolled once the drug was restarted. Wendling et al. [23] reported that postoperative RA
flares were observed in 6 cases (12%) and significantly associated with anti-TNF interrup‐
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tion before surgery (5 interruptions/6 cases of flare vs. 13 interruption/44 cases without flare;
Fisher’s exact value=0.02). Kawakami et al. [27] reported that RA flares during the perioper‐
ative periods were found in 17.2% (11/64) of anti-TNF group. These flares were significantly
increased in ETN group (31.0%, 9/29) compared with the IFX group (5.7%, 2/35) (P=0.009).
The reason for increased risk of postoperative RA flare in ETN compared with IFX is un‐
clear, but considered as follows. The half-life of IFX is longer than that of ETN, and in the
IFX group, the surgery was usually performed in the middle of the 8-week treatment of peri‐
od, and there was actually no withholding of anti-TNF therapy. Moreover, the function of
IFX is based on an antigen-antibody reaction, whereas the function of ETN is a reversible
connection response of ETN of TNF [27, 44].
On the other hand, intensive treatment with TNF blockers and MTX leads to clinical remission
in approximately 20-50% of RA patients. This excellent clinical result raised a new problem,
whether the patients with RA on TNF therapy can discontinue their therapy after acquisition of
low disease activity (LDA). In the BeST study [45], 67% of RA patients treated early with combi‐
nation of IFX and MTX were able to stop anti-TNF treatment. Brocq et al. [46] performed a small
prospective cohort study to determine the time to relapse after cessation of TNF antagonist ther‐
apy. The mean disease duration was 11.3 years. Amongst the 20 patients, three quarter (75%) re‐
lapsed within the first 12 months with the mean time to relapse of 15 weeks. Saleem et al. [47]
reported comparative data for patients treated early (n=27) versus late (n=20) with combination
therapy of MTX and anti-TNF. All patients fulfilled the criteria of clinical remission for at least 6
months. Anti-TNF therapy was then discontinued, while remaining on MTX for 24 months. The
primary outcome measure was a flare of the disease determined by an increase in Disease Activ‐
ity Score (DAS). At 24 months, there were significantly more patients in the initial treatment
group that had sustained remission compared with the delayed treatment group (59% vs. 15%,
P=0.003). Shorter disease duration was found for be a predictor of sustained remission follow‐
ing cessation of TNF blockers. Tanaka et al. [48] conducted a multicenter study (remission in‐
duction by Remicade in RA; RRR study) to determine whether IFX might be discontinued after
achievement of LDA in patient with RA and to evaluate progression of articular destruction
during the discontinuation. 114 RA patients with RA who had received IFX treatment, and dis‐
continued the drug after achieving DAS 28<3.2 (LDA) for >24 weeks, were studied. The mean
disease duration of the 114 patients was 5.9 years, mean DAS28 5.5 and modified total Sharp
score (mTSS) 63.3. 12 patients withdrew from the study. Out of the 102 patients, 56 patients
(55%) remained to have DAS 28<3.2 (RRR-achieved group) and 44 patients (43%) reached DAS
28<2.6 at 1 year after discontinuing IFX. On the other hand, 29 patients flared within 1 year
(mean duration 6.4 months) after the discontinuation and in 17 patients DAS28 was >3.2 at 1
year. Thus, the remission induction by IFX was failed in 46 patients (45%) at 1 year after the dis‐
continuation (RRR-failed group). Yearly progression of mTSS (ΔTSS) remained <0.5 (structural
remission) in 67% and 44% of the RRR-achieved and RRR-failed group, respectively. Patients
for whom RRR was achieved were younger (49.5 vs. 56.1 years), their disease duration was
shorter (4.8 vs. 7.8 years) and mTSS was lower (46.9 vs. 97.2) than for those whom RRR failed.
DAS28 at RRR-study entry had the most marked correlation with the maintenance of LDA for 1
year after the discontinuation. They concluded that after attaining LDA by IFX, 55% of the pa‐
tients with RA able to discontinue IFX for >1 year without progression of radiological articular
Perioperative Surgical Site Infections and Complications in Elective Orthopedic Surgery in Patients with...
http://dx.doi.org/10.5772/54012
121
progression. Klarenbeek et al. [49] conducted a study using five-year data of the BeSt study to
determine the relapse rate after discontinuing treatment in patients with RA in sustained clini‐
cal remission, to identify predictors of relapse and evaluate treatment response after restarting
treatment. 508 patients with recent-onset RA were randomized into four dynamic treatment
strategies, aiming at DAS≦2.4. When DAS was <1.6 for≧6months, the last DMARD was ta‐
pered and discontinued. If DAS increased ≧1.6, the last DMARD was immediately reintro‐
duced. 115/508 patients (23%) achieved drug-free remission during a five-year period. Of these
53/115 patients (46%) restarted treatment because the DAS≧1.6 after a median of 5 months,
59/115 patients (51%) remained drug-free remission for median duration of 23 months. To focus
the group of initial combination with IFX (n=128), 36/128 patients (28%) achieved drug-free re‐
mission during a five-year period. Of these 15/36 patients (42%) restarted treatment, 21/36 pa‐
tients (58%) remained drug-free remission. Of the 53 patients who restarted treatment, 39 (74%)
again achieved remission 3-6 months after the restart without showing radiological progres‐
sion during the relapse.
As mentioned above, after maintaining LDA by intensive treatment with TNF blockers, dis‐
continuation of TNF blockers without disease flare, joint damage progression, and function‐
al impairment is possible in some RA patients. Patients with shorter disease duration are
more likely to remain in remission after discontinuing TNF blockers compared to their
counterparts with established disease [45-48]. Furthermore, patients with longstanding dis‐
ease are more likely to have orthopaedic surgical intervention, especially prosthetic surgery,
compared to those with early disease. However, the significance of discontinuation of anti-
TNF therapy in perioperative periods is different from the cessation after achievement of
LDA. Because perioperative discontinuation of anti-TNF therapy is basically temporary, and
the therapy is restarted promptly after confirmation of good wound healing and no evi‐
dence of infection. Therefore, if TNF blockers are withheld prior to surgery, those with lon‐
ger disease duration need to be monitored carefully for features of relapse [36].
In summary of this section, perioperative discontinuation of anti-TNF therapy in elective or‐
thopaedic surgery likely caused postoperative RA flare. The risk of postoperative flare was
increased in ETN which had a shorter half-life compared with IFX, and also increased in the
patients with long disease duration. Shortening the period of withholding anti-TNF therapy
is desirable to prevent the postoperative flare, but shortening the duration of discontinua‐
tion may cause an increase in SSI and wound healing complications. This is the clinical di‐
lemma for orthopaedic surgeons. Data on this matter also insufficient to make definite
conclusion, thus further studies are clearly needed.
7. Recommended perioperative discontinuation period of anti-TNF-α
agents in national guidelines
Although the conclusions about the influences of continuation of anti-TNF therapy in perio‐
perative period on SSI, wound healing and RA flare are somewhat conflicting, but there are
few studies which recommend the perioperative continuation of anti-TNF therapy positive‐
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ly. The national guidelines on each society recommend preoperative discontinuation of TNF
blockers and show the preoperative off-period based on the half-life of each agents (Table 1).
mean half-life 2 half-lives 3 half-lives 5 half-lives
(days) (days) (days) (days)
Infliximab (IFX) 8-10 16-20 24-30 40-50
Etanercept (ETN) 4.3 8.6 12.9 21.5
Adalimumab (ADA) 14 28 42 70
Golimumab (GOL) 12 24 36 60
Certolizumab (CTZ) 14 28 42 70
Table 1. Mean half-lives of TNF blockers
The current American Society of Rheumatology (ACR) guidelines (2008) state that anti-TNF
should not be used during the preoperative period, for at least 1week prior to and 1 week
after surgery. It was recommended this decision should be further tempered by the pharma‐
cokinetic properties of a given biologic agent (e.g., longer periods of time off therapy may be
appropriate when using agents with longer half-lives.), and the type of surgery [50].
The recently updated British Society of Rheumatology (BSR) guidelines (2010) propose as
follows. In RA patients on anti-TNF, the potential benefit of preventing postoperative infec‐
tions by stopping treatment (different surgical procedures pose different risks of infection
and wound healing) should be balanced against the risk of a perioperative flare in RA activi‐
ty. If anti-TNF is to be stopped before surgery, consideration should be given TNF blockers
three to five times the half-life of the relevant drug prior to surgery and should not be re‐
started after surgery until there is good wound healing and no evidence of infection [51].
The Club Rhumatismes et Inflammation (CRI) (French Society of Rheumatology) provides
guidelines that based on drug half-lives and clinical settings. For minor surgery, in a sterile
setting with minor risk infection, IFX, ADA and ETN should be withheld, respectively, at
least 1 month, 3-4 weeks and 1-2 weeks. However, for surgery performed in a septic envi‐
ronment, the respective duration for interruption of IFX, ADA and ETN are 8, 4-6 and 2-3
weeks [52].
Recently updated the Board of Japan College of Rheumatology (JCR) guidelines (2012) cau‐
tion that surgery should be delayed until a sufficient time had elapsed from the last admin‐
istration of TNF-α antagonists (recommend to keep 2-4 weeks for ETN or 4 weeks for IFX
with long half-life), because it is not clear whether or not TNF-α blockade interferes with the
healing of wounds and prevention of postoperative infection. Treatment with TNF-α antag‐
onists could be resumed after complete healing of the surgical wound and in the absence of
any postoperative infection [53].
The Canadian Rheumatology Association (CRA) guidelines state that biologic DMARD
should be held prior to surgical procedures. The timing for withholding biologic DMARD
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should be based on the individual patient, the nature of the surgery, and the pharmacoki‐
netic properties of the agent. Biologic DMARD may be restarted postoperatively if there is
no evidence of infection and wound healing is satisfactory [54].
In clinical practice, we should follow each one’s national guidelines and medical circum‐
stance of each country. We summarized concisely the recommendations of main national
guidelines in Table 2.
Recommended perioperative management of TNF blockers
American Society of
Rheumatology (ACR)
*Discontinue for at least 1week prior to and 1 week after surgery
(this decision should be further tempered by the pharmacokinetic
properties of a given biologic agent and the type of surgery)
British Society of
Rheumatology (BSR)
*Discontinuation should be balanced against the risk of a
perioperative RA flare (three to five times the half-life of the relevant
drug prior to surgery) *Should not be restarted after surgery until
there is good wound healing and no evidence of infection
Club Rhumatismes et
Inflammation (CRI)
*Minor surgery: discontinue for at least 1 month (infliximab), 3-4
weeks (adalimumab) and 1-2 weeks (etanercept) *Surgery in a
septic environment: discontinue for 8 weeks (infliximab), 4-6 weeks
(adalimumab) and 2-3 weeks(etanercept)
Japan College of
Rheumatology (JCR)
*Discontinue for 2-4 weeks (etanercept) or 4 weeks (infliximab)
*Could be resumed after complete healing of the surgical wound
and in the absence of any postoperative infection
Canadian Rheumatology
Association (CRA)
*Discontinuation should be based on the individual patient, the
nature of the surgery, and the pharmacokinetic properties of the
agent. *Restarted postoperatively if there is no evidence of infection
and wound healing is satisfactory
Table 2. Recommendations for perioperative management of TNF blockers in national guidelines
8. Conclusions
It is difficult to draw definite conclusion on the influence of perioperative use of TNF block‐
ers on the risk of SSI, wound healing and flare of disease activity in RA patients undergoing
orthopaedic surgery, due to the retrospective nature and small sample size of most of past
studies. Although we have a limitation in the review of the perioperative management of
TNF blockers, it is seemed for us that perioperative discontinuation of anti-TNF therapy was
preferable to decrease the risk of SSI and wound healing complication, whereas it likely
caused the increased risk of RA flare. At present, the national guidelines on each society rec‐
ommend preoperative discontinuation of TNF blockers.
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The risk  factors  for  SSIs,  which most  of  RA patients  undergoing TJA are  considered to
have,  are  the  use  of  TNF blockers,  increased daily  steroid intake,  older  age and longer
disease  duration,  history  of  prior  SSI  or  skin  infection,  and  “clean”  surgical  procedure
such as TJA, thus it may be preferable to perform TJA, if needed, before the induction of
TNF blockers.  When withholding the anti-TNF therapy, the potential  benefit  of prevent‐
ing SSI (different surgical procedures pose different risks of infection and wound healing)
should be balanced against the risk of RA flare, and we should also take pharmacokinetic
properties  of  the  agents  into  consideration.  Shortening  the  period  of  withholding  anti-
TNF therapy is desirable to prevent the postoperative flare, but it may cause an increase
in SSI and wound healing complications. This is the clinical dilemma for orthopaedic sur‐
geons.  Further larger prospective studies are clearly needed to make definite conclusion
of perioperative management of TNF blockers, and in clinical practice until these studies
are done, we should follow each one’s national guidelines and take a sufficient antibiotic
prophylaxis with a careful follow-up.
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